SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
暂无分享,去创建一个
C. Zoccali | A. Ortiz | G. London | Z. Massy | E. Porrini | J. Valdivielso | D. Fouque | F. Mallamaci | R. Ekart | P. Sarafidis | R. Hojs | C. Ferro | K. Khazim | E. Morales | J. Małyszko | A. Wiecek | M. Hornum | P. Ruggenenti